Foghorn Abandons Uveal Melanoma Program after Subpar Phase I Results

Foghorn Therapeutics will no longer advance studies of a potential treatment for uveal melanoma—a rare and advanced form of cancer—after disappointing Phase I clinical results, the company announced Wednesday. Instead, it will advance the treatment for acute myeloid leukemia.